HAIFA, Israel--(BUSINESS WIRE)--March 11, 2004-- Pluristem Life Systems, Inc. (OTCBB:PLRS - News), a biotechnology company dedicated to the expansion of stem cells to address a myriad of fatal illnesses, today announced that the Company appointed Professor Tsvee Lapidot from the Weizmann Institute of Science, Israel as scientific advisor, specifically to analyze Pluristem's HSC expansion technology in animal models.

Prof. Tsvee Lapidot is presently The Pauline Recanati Career Development Chairman of Immunology at the Weizmann Institute of Science, Israel. The main focus of his research is the Mechanism of Human Stem Cell Migration and Development and the Role of Stromal Cells, Cytokines and Chemokines, in Hematopoiesis in vivo. His professional associations include, but are not limited to: member of American Society of Hematology and International Society of Experimental Hematology.

Prof. Lapidot's well-known expertise precedes his name in the field of hematopoietic stem cells. As Pluristem's expert in this area, he will act as an advisor in conducting stem cell repopulation capabilities using the SCID-NOD model (immune deficient mice). The SCID-NOD mouse provides an excellent system for analyzing human Hematopoietic Stem Cells (HSC's) and was proven a valuable tool in the study of human HSC's.

"The contributions Prof. Lapidot will bring to Pluristem as the Company enters pre-clinical trials are vital. His background and experience in HSC's will provide us with the most expert guidance that exists in the field today," stated Dr. Irit Arbel, CEO.

About Pluristem

Pluristem is a biotechnology company dedicated to the development of stem cell expansion technology. Pluristem's core technology is designed to expand hematopoietic stem cells from cord blood for bone marrow transplantations using the PluriX(TM) bioreactor. The unique quality of the PluriX(TM) Bioreactor is its ability to create a 3-D microenvironment that closely resembles the structure and function of the natural bone marrow environment. Upon successful development and regulatory approval, this technology should provide critical stem cell expansion services to cord blood banks and transplants centers in the U.S. and Europe.

For more information, visit the Company's website at: www.pluristem.com.

Safe Harbor Statement

Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding: our developing stem cell technology into a useful product that could address fatal illnesses, that our system can support the growth and reproduction of stroma cells to allow the expansion of hematopoietic stem cells from Cord Blood and that the PluriX bioreactor system creates a 3-D artificial physiological environment in which the stem cells can be expanded to quantities large enough for several adult transplants. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to complete its obligations under the stem cell license agreement, inability to finance the planned development of the technology, inability to obtain regulatory approval for commercial use of our products and unforeseen technical difficulties in developing the stem cell technology, which could among other things, delay or prevent product release. For further risk factors see Pluristem's filings with the SEC.

---

Contact:

     DeMonte Associates
     Investors:
     Cynthia DeMonte, 212-605-0525
     cdemonte@demonte.com